Posted by Michael Wonder on 11 Oct 2021
Ocular Therapeutix announces FDA approval of supplemental new drug application for Dextenza (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itching associated with allergic conjunctivitis
11 October 2021 - Approval represents the first primarily office-based indication for Dextenza.
Ocular Therapeutix today announced the U.S. FDA has approved its supplemental new drug application to broaden the Dextenza label to add an additional indication for the treatment of ocular itching associated with allergic conjunctivitis.
